Erasca, Inc. (ERAS) stock
ERASNasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.89−1.22 (-8.07%)
Close on Nov 17, 2026Market cap $4.86BP/E –Yield 0.00%
Erasca r&d expenses
Research and development expenses are spending on new products and technology.
Erasca's R&D Expenses for the twelve months ending Jun 30, 2026 was $108.88M, up 7.9% year over year. For fiscal 2025 it was $92.85M, down 19.5% from the year before. The highest annual figure on record is $115.36M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $92.85M | -19.5% |
| FY2024 | Dec 31, 2024 | $115.36M | +11.1% |
| FY2023 | Dec 31, 2023 | $103.82M | -7.7% |
| FY2022 | Dec 31, 2022 | $112.46M | +52.1% |
| FY2021 | Dec 31, 2021 | $73.92M | +150.2% |
| FY2020 | Dec 31, 2020 | $29.55M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $35.90M | +69.6% |
| Q1 FY2026 | Mar 31, 2026 | $27.27M | +5.0% |
| Q4 FY2025 | Dec 31, 2025 | $23.24M | -11.0% |
| Q3 FY2025 | Sep 30, 2025 | $22.47M | -18.7% |
| Q2 FY2025 | Jun 30, 2025 | $21.17M | -35.9% |
| Q1 FY2025 | Mar 31, 2025 | $25.97M | -9.1% |
| Q4 FY2024 | Dec 31, 2024 | $26.12M | +5.3% |
| Q3 FY2024 | Sep 30, 2024 | $27.63M | +9.6% |
| Q2 FY2024 | Jun 30, 2024 | $33.03M | +26.0% |
| Q1 FY2024 | Mar 31, 2024 | $28.57M | +3.6% |
| Q4 FY2023 | Dec 31, 2023 | $24.81M | -15.5% |
| Q3 FY2023 | Sep 30, 2023 | $25.21M | -10.5% |
| Q2 FY2023 | Jun 30, 2023 | $26.22M | -4.6% |
| Q1 FY2023 | Mar 31, 2023 | $27.59M | +0.6% |
| Q4 FY2022 | Dec 31, 2022 | $29.36M | +21.7% |
| Q3 FY2022 | Sep 30, 2022 | $28.18M | +41.3% |
| Q2 FY2022 | Jun 30, 2022 | $27.49M | +56.2% |
| Q1 FY2022 | Mar 31, 2022 | $27.43M | +124.0% |
| Q4 FY2021 | Dec 31, 2021 | $24.13M | +139.7% |
| Q3 FY2021 | Sep 30, 2021 | $19.95M | +120.0% |
| Q2 FY2021 | Jun 30, 2021 | $17.60M | +200.2% |
| Q1 FY2021 | Mar 31, 2021 | $12.25M | – |
| Q4 FY2020 | Dec 31, 2020 | $10.07M | – |
| Q3 FY2020 | Sep 30, 2020 | $9.07M | – |
| Q2 FY2020 | Jun 30, 2020 | $5.86M | – |
See a number that looks wrong?